Clinical trials: Tamoxifen
Cardiovascular Diseases, Breast Neoplasms
Raloxifene Use for The Heart
The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.
- Trial name
- NCT00190593
- Testing
- raloxifene
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma
- Trial name
- LoTam (NCT06671912)
- Testing
- Anastrozole, Letrozole, Exemestane
- Where
- 732 sites in United States, Puerto Rico
- Volunteers
- 1,556 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Neoplasm Metastasis, Osteosarcoma
A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma
The suppression of IGF-I and growth hormone may significantly alter the pathobiology of osteosarcoma. SMS 201-955 pa LAR is a long acting analog of Somatostatin which inhibits the pituitary release of growth hormone, reducing…
- Trial name
- NCT00001436
- Testing
- OncoLAR® (Registered Trademark), tamoxifen
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Radiation Therapy and Tamoxifen in Treating Children With Newly Diagnosed Brain Stem Glioma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Tamoxifen may kill tumor cells by blocking the enzymes necessary for cell growth.
- Trial name
- NCT00024336
- Testing
- tamoxifen citrate, radiation therapy
- Where
- 22 sites in Ireland, United Kingdom
- Sponsor
- Children's Cancer and Leukaemia Group
Breast Cancer
Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast Cancer
RATIONALE: High estrogen levels may be associated with dense breast tissue and an increased risk of developing breast cancer. Tamoxifen may be effective in reducing breast density by decreasing estrogen levels.
- Trial name
- NCT00086749
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
This phase II trial tests the accuracy of functional imaging (FFNP)-positron emission tomography (PET)/computed tomography (CT) to predict response to abemaciclib plus endocrine therapy.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma, Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma
- Trial name
- NCT06179303
- Testing
- Abemaciclib, Anastrozole, Biospecimen Collection
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Washington
HER2/Neu Negative, Invasive Breast Carcinoma
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
This pilot clinical trial studies how well endocrine therapy works in treating patients with HER2 negative, low risk breast cancer. Estrogen can cause the growth of breast cancer cells.
- Conditions
- HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal, Stage 0 Breast Cancer
- Trial name
- NCT03238703
- Testing
- Anastrozole, Exemestane, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer Invasive
Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial)
DELFINO tial is designed to investigate the role of "OFS add on to TMX ", based on MMG density as a surrogate marker in premenopausal women Premise - MMG density as a surrogate marker of hormone therapy Assumption - "Add on OFS…
- Trial name
- NCT03664895
- Testing
- Leuplin or zoladex
- Where
- South Korea
- Volunteers
- 224 people
- Sponsor
- Seoul National University Hospital
Metastatic Breast Cancer
ER Reactivation Therapy for Breast Cancer
Before anti-estrogens such as tamoxifen were developed to treat estrogen receptor (ER)-positive breast cancer, high-dose estrogen therapies were used.
- Trial name
- POLLY (NCT02188745)
- Testing
- 17B-estradiol, Letrozole, Anastrozole
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Metastatic Breast Cancer, HER2-negative Breast Cancer
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
- Conditions
- Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
- Trial name
- TRACY-1 (NCT06590857)
- Testing
- RYZ101, Standard of Care Endocrine Therapy
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 64 people
- Sponsor
- RayzeBio, Inc.
Postmenopause
AFTER: Altering Fat Through Estrogen and Raloxifene
The purpose of this study is to determine whether estrogens specifically promote a reduction in fat from abdominal regions during weight loss and/or prevent the accumulation of abdominal fat during weight gain.
- Trial name
- NCT00149604
- Testing
- conjugated estrogens, Raloxifene, exercise plus mild caloric restriction for weight loss
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Endometrial Cancer
Combination Chemotherapy Compared With Hormone Therapy in Treating Patients With Recurrent, Stage III, or Stage IV Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells.
- Trial name
- NCT00016341
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- 50 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Breast Cancer, Adjuvant Treatment
Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
Researchers have learned that about 50% of women do not finish the standard 5-year breast cancer treatment with an aromatase inhibitor.
- Conditions
- Breast Cancer, Adjuvant Treatment, Early Stage Breast Cancer
- Trial name
- SWIVEL (NCT07071038)
- Testing
- Switch, Guideline Directed Intervention (GDI)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Cancer
Sexual Coercion in Breast Cancer Patients Treated With Luteinizing Hormone-Releasing Hormone Agonists (LHRHa )
The use of luteinizing hormone-releasing hormone agonists(LHRHa) to suppress ovarian function is a common strategy for treating premenopausal, hormone receptor-positive breast cancer.
- Trial name
- LHRHa (NCT06840847)
- Testing
- Sexual Coercion
- Where
- Turkey (Türkiye)
- Volunteers
- 79 people
- Sponsor
- Canan Kas
Breast Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- 15-95 (NCT00002784)
- Testing
- filgrastim, CMF regimen, cyclophosphamide
- Where
- 11 sites in Australia, Switzerland
- Volunteers
- 344 people
- Sponsor
- ETOP IBCSG Partners Foundation
Liposarcoma, Prostate Cancer
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy.
- Conditions
- Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- CDK4i (NCT04557449)
- Testing
- PF-07220060, Letrozole, Fulvestrant
- Where
- 39 sites in United States, Argentina and 6 more
- Volunteers
- 430 people
- Sponsor
- Pfizer
Osteoporosis
Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?
Current osteoporosis therapies produce a prompt increase in bone mass, followed by only modest or no further subsequent gains. This limitation, known as the "remodeling transient," reflects the "coupling" of bone resorption with…
- Trial name
- NCT01166958
- Testing
- Teriparatide, Raloxifene
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
This phase II trial studies how well giving combination chemotherapy and peripheral blood stem cell transplant followed by aldesleukin and sargramostim works in treating patients with inflammatory stage IIIB or metastatic stage…
- Conditions
- Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer
- Trial name
- NCT00003199
- Testing
- tamoxifen citrate, busulfan, thiotepa
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Retroperitoneal Fibrosis
Prednisone Versus Tamoxifen in Idiopathic Retroperitoneal Fibrosis
Idiopathic retroperitoneal fibrosis (IRF) is a rare disease characterised by the presence of a retroperitoneal periaortic fibro-inflammatory tissue which may entrap the ureters and cause renal failure.
- Trial name
- NCT00440349
- Testing
- Tamoxifen, Prednisone
- Where
- Italy
- Volunteers
- 38 people
- Sponsor
- University of Parma
Oligoasthenoteratozoospermia, Male Infertility
Efficacy Comparison of Tamoxifen and Tamoxifen With Antioxidants on Semen Quality of Male With Idiopathic Infertility
Objective of the study is to compare the efficacy of tamoxifen alone \& tamoxifen with antioxidant on semen quality of infertile male with abnormal parameters (sperm count, motility, vitality, morphology) .Infertility is defines…
- Trial name
- NCT05200663
- Testing
- Tab Tamoxifen 10 mg, Tab Tamoxifen 10mg,Cap vitamin E 400mg
- Where
- Pakistan
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Sharif Medical Research Center